InMed Pharmaceuticals Inc. announced the Company has entered into a service contract (the Contract) with Brio Financial Group (Brio) to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2632 USD | -4.05% | +8.76% | -36.73% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.73% | 1.59M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- INM Stock
- News InMed Pharmaceuticals Inc.
- InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer